Estradiol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Estradiol
- Estradiol: From Unrecorded Original Indication to Symptomatic Form of Fragile X Syndrome in Female Carriers
Estradiol: From Unrecorded Original Indication to Symptomatic Form of Fragile X Syndrome in Female Carriers
One-Sentence Summary
This Evidence Pack does not contain Estradiol’s original approved indication or mechanism-of-action data (both marked as data gaps), and the drug currently has 0 marketing authorizations in this jurisdiction. TxGNN’s top-ranked candidate is Symptomatic Form of Fragile X Syndrome in Female Carrier, with a prediction score of 98.76%, but this is currently supported by zero clinical trials and zero publications — a pure model prediction with no mechanistic or empirical backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file (no original indication or license data provided) |
| Predicted New Indication | Symptomatic form of fragile X syndrome in female carrier |
| TxGNN Prediction Score | 98.76% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this Evidence Pack for Estradiol, and no original indication was captured either — both are flagged as data gaps (MOA: High severity, TFDA label/warnings: Blocking severity). This limits our ability to assess mechanistic plausibility against a known baseline indication.
For the predicted indication itself, the rationale provided is explicit: there is no known mechanistic relationship between estradiol and FMR1-related X-linked fragile X syndrome. Fragile X syndrome in female carriers arises from a CGG-repeat expansion in the FMR1 gene, a genetic/neurodevelopmental mechanism unrelated to estrogen receptor signaling. The 98.76% score therefore reflects the TxGNN knowledge-graph embedding model’s output alone (rank 11,373 among all predictions), with no corroborating clinical trial or literature evidence — consistent with the L5 “model prediction only” classification already assigned in this pack.
Notably, this Evidence Pack contains other, better-evidenced Estradiol candidates further down the ranked list — most prominently anovulation (rank 2, L3 evidence, 42 clinical trials and 20 publications, including a physiologically direct role for estradiol in endometrial preparation and ovulation induction protocols). If a repurposing signal is being pursued for Estradiol, that candidate merits separate evaluation; it is not covered by this report because the template scope is fixed to the top-ranked (rank 1) candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5, model-only prediction with no clinical trials, no literature, and no known mechanistic link between estradiol and fragile X syndrome — the rationale data explicitly states the connection is “purely a model prediction score.” There is no basis to advance this candidate past the research-hypothesis stage.
To proceed, the following is needed:
- TFDA label / SmPC warnings and contraindications (currently blocking — required before any S1 safety screening can occur)
- Estradiol mechanism-of-action data from DrugBank (currently missing — needed for mechanistic relevance analysis)
- Basic original-indication and licensing data for Estradiol (currently absent from this pack, and the drug shows 0 marketing authorizations)
- If repurposing interest continues, in vitro/in vivo studies testing any estrogen-pathway involvement in FMR1-related pathology, since none currently exist
- Consider redirecting evaluation effort to the anovulation candidate (rank 2), which already has L3 evidence (42 trials, 20 publications) and a plausible physiological rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.